Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

IGBA Puts Together Global Leadership Alliance

CEO Advisory Committee Provides Forum For Leaders To Engage On Key Issues

Executive Summary

Leaders from a host of the world’s top generics and biosimilars companies have come together as part of a CEO advisory committee put together by the IGBA. The committee is expected to provide a forum to share thinking on key issues affecting the off-patent industry and best position the industry on critical policy issues with a single collective voice.

You may also be interested in...



Lupin’s Gupta Moves Up To Lead IGBA Leadership Committee

Lupin CEO Vinita Gupta will next year take over from Sandoz chief executive Richard Saynor as chair of the IGBA’s CEO advisory committee, representing the voice of the global off-patent industry. At the same time, Insud CEO Lucas Sigman will take over from Gupta as vice-chair.

IGBA Leaders Open Up Talks With WIPO

The IGBA’s CEO advisory committee of top off-patent industry leaders has met with Daren Tang, director general of the WIPO, to discuss the importance of a balanced global intellectual property regime.

IGBA CEO Panel Sets Out Priorities For Supply-Chain Resilience

After a meeting in Vienna, the IGBA’s CEO advisory committee has outlined four key areas in which action is needed to bolster supply-chain security and ensure pandemic prevention, preparedness and response.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

GB151623

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel